Anbenitamab to gain competitive edge in China’s HER-positive gastric cancer market
China’s National Medical Products Administration (NMPA) has recently accepted the New Drug Application (NDA) of Alphamab Oncology’s (HK: 9966) nKN026 (anbenitamab).
If approved, KN026 is expected to become the first bispecific monoclonal antibody (MAb) targeting HER2-positive gastric or gastroesophageal (GEJ) carcinoma and evolve as a potential treatment option in the gastric cancer landscape in China, says pharma analytics company GlobalData.
KN026’s bispecific receptor blockade mechanism enables simultaneous binding to two HER2 epitopes, effectively blocking the HER2 signals. The NDA submission is supported by results from the Phase II/III KN026-001 trial. KN026, combined with chemotherapy for adult patients with HER2-positive locally advanced, recurrent, or metastatic gastric or GEJ adenocarcinoma who have failed at least one prior systemic therapy containing trastuzumab, demonstrated an improved progression-free survival (PFS) and overall survival (OS) compared to standard-of-care with no new safety concerns in the trail.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze